Curis, Inc.

507 articles about Curis, Inc.

• Curis Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

  12/8/2020

  - Reduction of marrow blasts observed in all evaluable patients - - Marrow complete response observed in 2 patients - - Management to host virtual KOL event today, Tuesday, December 8 at 8:00 a.m. ET -

• Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

  12/7/2020

  - Tumor reductions observed in 6 of 7 patients treated at 300 mg BID following median 4 prior lines of therapy - - Patients receiving 300 mg BID have remained on therapy for extended periods of time (1 to 2 years) - - Two potential biomarkers identified that demonstrate target engagement and highlight potential for patient enrichment strategy - - Recommended Phase 2 dose of 300 mg BID balances durable anti-cancer activity and extended tolerability profile -

• Curis to Host Virtual Event to Discuss CA-4948 Clinical Data

  12/2/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a virtual KOL event on Tuesday, December 8, 2020, at 8:00 am ET.

• Curis Reports Third Quarter 2020 Financial Results

  11/10/2020

  - Clinical data in CA-4948 NHL and AML/MDS trials to be presented in oral presentation and poster sessions at ASH - - Patient Dosing initiated in Phase 1a/1b trial of anti-VISTA monoclonal antibody, CI-8993, in advanced refractory solid tumors - - Initiation planned for Phase 1 trial of CA-4948 in combination with ibrutinib in NHL -

• Curis Announces Collaboration with the National Cancer Institute for the Development of IRAK4 Inhibitor, CA-4948, as an Anti-Cancer Agent

  11/10/2020

  Curis, Inc. announced that it has entered into a Cooperative Research and Development Agreement with the National Cancer Institute, a component of the National Institutes of Health, for joint development of CA-4948, a first-in-class small molecule IRAK4 kinase inhibitor, as an anti-cancer agent under the NCI Experimental Therapeutics Program.

• Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition

  11/4/2020

  Curis, Inc. announced that three abstracts for CA-4948, a small molecule IRAK4 inhibitor, have been accepted for oral and poster presentation at the 62nd American Society of Hematology Annual Meeting and Exposition which will be held virtually from December 5-8, 2020.

• Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference

  11/4/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer , President and Chief Executive Officer of Curis, will present at the H.C. Wainwright & Co. 6 th Annual Israel Conference on Thursday, November 12, 2020

• Curis to Release Third Quarter 2020 Financial Results and Hold Conference Call on November 10, 2020

  11/2/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of US markets.

• Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies

  10/21/2020

  Curis, Inc. highlighted a paper published online in ACS Medicinal Chemistry Letters, a peer-reviewed publication of the American Chemical Society, titled, "Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies." The paper describes the preclinical work done to select CA-4948 and its on-target engagement and inhibition of IRAK4 in various animal studies.

• Curis to Present at Upcoming Investor Conferences

  9/10/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will provide a company overview at two upcoming investor conferences:

• Curis Reports Second Quarter 2020 Financial Results

  8/4/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2020.

• Curis to Release Second Quarter 2020 Financial Results and Hold Conference Call on August 4, 2020

  7/28/2020

   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2020 financial results on Tuesday, August 4, 2020 , after the close of US markets. Management will host a conference call on the same

• Curis Doses First Patient in Phase 1 Study of CA-4948 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

  7/7/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948,

• Curis Announces $17.5 Million Registered Direct Offering

  6/11/2020

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that it has entered into definitive agreements with fundamental healthcare investors for the purchase and sale of 14,000,000 of its shares of common stock at a purchase price of $1.25 per share in a registered direct offering.

• Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody

  6/10/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigati

• Curis Reports First Quarter 2020 Financial Results

  5/12/2020

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the first quarter ended March 31, 2020.

• Curis to Release First Quarter 2020 Financial Results and Hold Conference Call on May 12, 2020

  5/5/2020

   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter 2020 financial results on Tuesday, May 12, 2020 , after the close of US markets. Management will host a conference call on the same day a

• Curis to Present at 19th Annual Needham Virtual Healthcare Conference

  4/7/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. ET

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 3, 2020

  4/3/2020

  Curis, Inc. announced that on April 1, 2020, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 110,000 shares of Curis common stock to three new employees, with a grant date of April 1, 2020.

• Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

  3/19/2020

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2019.